RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-5.97%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$522M
AUM Growth
+$522M
(-17%)
Cap. Flow
-$70.4M
Cap. Flow
% of AUM
-13.5%
Top 10 Holdings %
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11
Top Buys
| 1 |
Gilead Sciences
GILD
|
$18.6M |
| 2 |
Medtronic
MDT
|
$15.3M |
| 3 |
Pfizer
PFE
|
$10.8M |
| 4 |
Elevance Health
ELV
|
$8.38M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$5.42M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$26.6M |
| 2 |
CELG
Celgene Corp
CELG
|
$10.8M |
| 3 |
UnitedHealth
UNH
|
$8.8M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.56M |
| 5 |
Merck
MRK
|
$7.65M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Financials | 1.61% |
| 3 | Technology | 0.16% |
| 4 | Energy | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $18.6M | 3.57% | +259,894 | New | +$18.6M |
|
2
Bristol-Myers Squibb
BMY
$96B
| $16.4M | 3.15% | 281,000 +44,000 | +19% | +$2.57M |
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $16M | 3.06% | 76,000 -3,500 | -4% | -$735K |
|
4
Eli Lilly
LLY
$657B
| $15.8M | 3.03% | 215,000 -40,000 | -16% | -$2.94M |
|
|
5
Medtronic
MDT
$119B
| $15.3M | 2.94% | +215,240 | New | +$15.3M |
|
6
Incyte
INCY
$16.5B
| $14M | 2.69% | 140,000 -45,000 | -24% | -$4.51M |
|
7
Teva Pharmaceuticals
TEVA
$21.1B
| $13.1M | 2.5% | 360,000 +90,000 | +33% | +$3.26M |
|
8
Exelixis
EXEL
$10.1B
| $12.4M | 2.37% | 830,000 +230,000 | +38% | +$3.43M |
|
|
9
UnitedHealth
UNH
$281B
| $12M | 2.3% | 75,017 -54,983 | -42% | -$8.8M |
|
|
ABMD
10
DELISTED
Abiomed Inc
ABMD
| $11.6M | 2.22% | 102,700 +17,700 | +21% | +$1.99M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $11.3M | 2.17% | 700,000 +335,000 | +92% | +$5.42M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $11.2M | 2.15% | 91,702 -70,000 | -43% | -$8.56M |
|
|
ARIA
13
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $11.1M | 2.13% | 895,000 +220,000 | +33% | +$2.74M |
|
14
CVS Health
CVS
$92.8B
| $11M | 2.12% | 140,000 -20,000 | -13% | -$1.58M |
|
|
15
Pfizer
PFE
$141B
| $10.8M | 2.08% | +333,300 | New | +$10.8M |
|
|
CELG
16
DELISTED
Celgene Corp
CELG
| $10.8M | 2.06% | 93,000 -93,000 | -50% | -$10.8M |
|
17
Biogen
BIIB
$19.4B
| $10.2M | 1.96% | 36,000 -21,000 | -37% | -$5.96M |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.73M | 1.86% | 26,500 -3,000 | -10% | -$1.1M |
|
19
Amgen
AMGN
$155B
| $9.5M | 1.82% | 65,000 +10,000 | +18% | +$1.46M |
|
20
Cigna
CI
$80.3B
| $9.2M | 1.76% | 69,000 -15,000 | -18% | -$2M |
|
21
Centene
CNC
$14.3B
| $8.48M | 1.63% | 150,000 +70,000 | +88% | +$3.96M |
|
|
22
Elevance Health
ELV
$71.8B
| $8.38M | 1.61% | +58,257 | New | +$8.38M |
|
23
Zimmer Biomet
ZBH
$21B
| $8.26M | 1.58% | 80,000 -5,000 | -6% | -$516K |
|
24
Humana
HUM
$36.5B
| $8.16M | 1.56% | 40,000 +15,000 | +60% | +$3.06M |
|
25
HCA Healthcare
HCA
$94.5B
| $7.75M | 1.49% | 104,707 -5,293 | -5% | -$392K |
|